Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Introduces New Aquila 5Dretic 5-Part Differential Hematology Analyzer

By LabMedica International staff writers
Posted on 20 Nov 2019
Diatron (Budapest, Hungary) introduced its new high throughput, 5-part differential hematology analyzer with continuous loading autoloader for the first time at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. More...
The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

Diatron, a global provider of hematology and clinical chemistry analyzers, also showcased its P500 flagship clinical chemistry analyzer, and the Diatron KleeYa, an open, flexible CLIA platform, and demonstrated the Aquila 3-part diff hematology analyzer from its current hematology product portfolio.

The Diatron Aquila 5Dretics is the smallest and most compact cap piercing 5-part differential hematology analyzer with a maximum throughput of 80 tests per hour. It has a low reagent consumption (<30 ml), requires a small sample volume (40 ul) and has a continuous loading autoloader, making the walk away system convenient for all customers. It uses only two reagents as it is a fully optical system, resulting in low reagent consumption and making it more cost-effective. The Diatron Aquila 5Dretics requires little bench space (32 cm W x 30 cm D x 37 cm H without autoloader) and features a large touch screen, an intuitive user interface and a protected reagent pack system with unique connection

At the 2019 edition of MEDICA, Diatron also showcased its P500 flagship clinical chemistry analyzer. The P500 is an ergonomically designed, user-friendly system that offers a high level of automation and delivers assured result quality. The cost-effective, walkaway system is intended for medium throughput usage, providing results for 215 tests per hour on a typical sample mix. Also showcased at the event was Diatron KleeYa, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.

Additionally, Diatron demonstrated the Aquila 3-part diff hematology analyzer which offers a throughput of 60 tests per hour, requires a sample size of only 10µl, and consumes less than 10ml of reagent per test. It is equipped with an onboard reagent pack sufficient for approximately 200 measurements and includes a touchscreen, intuitive user interface, optional backup battery pack, and extended connectivity options.

Related Links:
Diatron


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.